In a recent event aimed to garner support among seniors, President Joe Biden highlighted the government’s efforts to implement new price caps on prescription drugs, a move notably aimed at curbing what he called “price gouging”. Bloomberg reports that according to Biden, the actions of pharmaceutical companies that increase drug prices at a rate faster than inflation are a “rip off”.
These strong words, from Biden, delivered at the National Institutes of Health, were targeted at the pharmaceutical makers, accusing them of ripping off not just Medicare but also the American people. The President highlighted that such price increases are not only imposing financial strains on consumers but also adding to the financial burden of the Medicare system.
The aforementioned caps on prescription drug prices come at the heels of legislation passed by the Democrats in the preceding year. The said legislation mandates pharmaceutical companies to pay rebates to Medicare if they increase the prices of certain drugs beyond the rate of inflation. These rebates, according to the legislation, are then utilized by the government to reduce the out-of-pocket expenses that patients need to bear.
The issue of mounting drug prices has long been a focus of contention and debate, and the new caps could be viewed as a significant attempt to rein in the soaring costs. This action appears to be a part of broader strategy by the Biden administration, seeking to shore up essential support ahead of the 2024 elections, particularly amongst the senior citizen demographic who are most affected by the issue. However, this bold approach is sure to elicit response from the pharmaceutical industry, and only time will reveal the full implications of these newly imposed price caps.
Legal professionals working in related verticals will no doubt be watching closely as the pharmaceutical companies formulate their responses and any potential legal ramifications unfold.